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Evaluate 503B Facilities for Outsourced Compounds

Complete Due Diligence Before Selecting a Compounding Pharmacy and
Establishing an Outsourcing Relationship
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HE US HEALTH care system has
encountered long-standing, complex
challenges, including growing costs,
overuse of care, staffing shortages and
supply chain weaknesses.
COVID-19 revived these pressures,
transforming the health care landscape.
Medication and staffing shortages plague
hospital systems, and pharmacies are not
exempt. Most health systems have experienced high levels of pharmacy technician
turnover, with most reporting a minimum
turnover rate of 21% last year. 1 In addition,
medication shortages of critical medications and infusions create significant workflow barriers that hospitals must address to
ensure patient safety. 2 In the face of these
obstacles, health systems are turning to
503B compounding facilities to outsource
pharmacy needs.
Before 2013, hospitals and surgical
centers either compounded medications in
house or depended on 503A pharmacies
for compounded medications. However, to
improve quality after high-profile cases of
infections from outsourced compounded
products were reported, the Drug Quality
and Security Act (DQSA) created FDA-registered 503B outsourcing facilities. 3 Since
2013, 503B outsourcing facilities have
produced and provided compounded sterile
preparations in large quantities under
DQSA. Registered 503B outsourcers must
comply with federal and state guidelines,
meet strict good manufacturing process
standards, and be routinely inspected by
the FDA.
However, pharmacy leaders are skeptical
of this change in process and must do due
diligence when selecting a 503B pharmacy
before moving into an outsourcing relationship. A multidisciplinary team should
undertake a standardized 503B vendor

evaluation process to give administrative
and clinical perspectives equal weight
and minimize risk. 4 The evaluation should
include not only ensuring appropriate
licensing and regulatory requirements but
also asking probing questions regarding
best practices, compliance, and quality
assurance. 5
The first step in evaluating a potential
503B vendor is ensuring that it meets
regulatory requirements. In October 2021,
the FDA released updated draft guidance
for 503B pharmacies recommending that
health systems use FDA-registered 503B
facilities. 6 Although this recent guidance
is only a recommendation, it ensures that
health systems meet the requirements for
minimizing the risk of contamination and
risks associated with low compounding
conditions. Because the FDA inspects
registered facilities and other regulatory
bodies, pharmacists can feel confident in
the products they are receiving. The state
board may require additional registration
of boards of pharmacy (BoP). However,
pharmacy leaders should double-check
with their state BoP as found through the
National Association of Boards of Pharmacy.
Before conducting the vendor interview,
however, the multidisciplinary team should
review all FDA inspection documents for
the 503B facility and pay particular attention if an FDA Form 483 has been filed, as
this indicates substandard conditions were
found during inspection. 1 Although an FDA
Form 483 may not preclude a 503B vendor
entirely, it does warrant consideration and
may drive additional questions for the
vendor. Other documents include audit
documents, clean room certifications, and
compounding and training records.
Within the compliance domain, questions
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“

If pharmacy leaders are screening vendors to
ensure that they are considering only those
that are FDA-registered, this will alleviate
considerable concerns within this domain.
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revolve around shifting compounding regulations. If pharmacy leaders are screening
vendors to ensure that they are considering
only those that are FDA-registered, this
will alleviate considerable concerns within
this domain. Questions may include how
microorganisms and particles are monitored,
what primary engineering controls are used,
whether the environment is monitored, who
the supplier or vendor of materials is, and
how they are qualified.
Within the domain of quality assurance,
the goal is to ensure that a 503B vendor
is consistently producing high-quality
compounds. A review of the local BoP may
provide additional information on the status
of the vendor facility and on disciplinary
actions that have been taken. 1
Questions may include what the compounding
process is, how employees are trained, what
studies are performed to test the products, and
what the quarantining process is.
The final domain for consideration is
best practices. Although 503B vendors are
relatively new to the health care world,
the importance of authority, honesty, and
transparency within the quality assurance
department remains unchanged. 6 Critical
questions for this domain include what the
authority and role of the quality assurance
department are, what the process is for
reporting adverse effects to patients, and
whether the quality assurance department
can reject or release the product.
Although evaluating a potential 503B
vendor may seem daunting, the risks of
entering a vendor agreement without a thorough review are far direr. Clinicians remain
liable for the compounds and their preparation even if that service is outsourced. 7
The focus on cost-effective care and patient
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safety has never been more monitored.
A thorough evaluation of all potential
503B vendors is the best insurance against
liability and the simplest way to ensure
patient safety. COVID-19 will continue to
affect the health care landscape for years.
Outsourcing facilities can play a critical
role in the hospital supply of ready-to-use
sterile drug products. ■
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